We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nepa Gene and Bulldog Bio Agree to a North American Partnership
Product News

Nepa Gene and Bulldog Bio Agree to a North American Partnership

Nepa Gene and Bulldog Bio Agree to a North American Partnership
Product News

Nepa Gene and Bulldog Bio Agree to a North American Partnership


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Nepa Gene and Bulldog Bio Agree to a North American Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nepa Gene CO., LTD., and Bulldog Bio Inc., have signed an agreement to establish Bulldog Bio as the sole distributor of the new NEPA21 Electro-kinetic Transfection System to laboratories in the US and Canada.

Capable of using off-the-shelf electroporation cuvettes, this device can boost efficiency and reduce cytotoxicity for in vitro transfection experiments - and without the need for expensive proprietary buffers.

Also, with over 100 electrode options for in vivo, ex vivo, in ovo and in situ applications, transfection of living tissues is possible.

“This patented, one-of-a-kind system has transformed what an electroporator is capable of doing. It creates complex and dynamic electrical fields in a wide variety of matrices, and has opened the vistas for electro-mediated transfection. And though we have had to wait almost 6 months while the infrastructure in Japan recovered from the natural disasters earlier this year, component suppliers are back online and the NEPA21 is now being produced on a predictable schedule.” Ella Fontaine, Vice President of Communications, elaborates “We are quite excited as this technology is already proven and has been used by researchers in Japan for a wide variety of non-in vitro application, from highly localized transfections in brain tissue, to general transfection of embryos, the possibilities are quite vast.”

Advertisement